Literature DB >> 23620441

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.

Margret E Bock1, Heather E Price, Lorenzo Gallon, Craig B Langman.   

Abstract

BACKGROUND AND OBJECTIVES: FSGS is the primary cause of childhood nephrotic syndrome leading to ESRD. Permeability factors, including circulating serum soluble urokinase-type plasminogen activator receptor (suPAR), have been postulated as putative causes in adults with primary FSGS. Similar results have yet to be proven in children. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This cross-sectional single-center study assessed the association of serum suPAR in children with FSGS or other glomerular and nonglomerular kidney diseases.
RESULTS: This study examined 110 samples retrieved from 99 individuals (between January 2011 and April 2012), aged 1-21 years; of these individuals, 20 had primary FSGS, 24 had non-FSGS glomerular disease, 26 had nonglomerular kidney disease, and 29 were healthy controls. suPAR levels were not significantly different in children with FSGS, non-FSGS glomerular disease, and healthy controls (P>0.05). However, suPAR levels (median [25%-75%]) were higher in children with nonglomerular kidney disease (3385 pg/ml [2695-4392]) versus FSGS (2487 pg/ml [2191-3351]; P<0.05). Female patients with nephrotic-range proteinuria (U-Pr/Cr >2) had lower suPAR levels than those without proteinuria (2380 pg/ml [2116-2571] versus 3125 pg/ml [2516-4198], respectively; P<0.001). This trend was not seen among male participants; suPAR levels in all female participants were lower than in male participants (P=0.03). Thirty-four patients studied were kidney transplant recipients; transplant status was not associated with suPAR levels in patients with FSGS or non-FSGS diagnoses, independent of proteinuria, race, or sex (P>0.05).
CONCLUSIONS: On the basis of these results, circulating suPAR is unlikely the leading cause for childhood idiopathic FSGS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23620441      PMCID: PMC3731904          DOI: 10.2215/CJN.07680712

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  31 in total

1.  Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).

Authors:  R J Hogg; R J Portman; D Milliner; K V Lemley; A Eddy; J Ingelfinger
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

Review 2.  Focal segmental glomerulosclerosis.

Authors:  Vivette D D'Agati; Frederick J Kaskel; Ronald J Falk
Journal:  N Engl J Med       Date:  2011-12-22       Impact factor: 91.245

3.  Serum-soluble urokinase receptor concentration in primary FSGS.

Authors:  Rutger J H Maas; Jack F M Wetzels; Jeroen K J Deegens
Journal:  Kidney Int       Date:  2012-05       Impact factor: 10.612

4.  The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.

Authors:  C F Sier; R Stephens; J Bizik; A Mariani; M Bassan; N Pedersen; L Frigerio; A Ferrari; K Danø; N Brünner; F Blasi
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

5.  Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.

Authors:  Kaija-Leena Kolho; Elsa Valtonen; Hanne Rintamäki; Erkki Savilahti
Journal:  Scand J Gastroenterol       Date:  2012-07-02       Impact factor: 2.423

6.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function.

Authors:  R J Shalhoub
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

7.  Recurrent focal glomerulosclerosis: natural history and response to therapy.

Authors:  M Artero; C Biava; W Amend; S Tomlanovich; F Vincenti
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

8.  Proteinuria in rats induced by serum from patients with collapsing glomerulopathy.

Authors:  Maria del Carmen Avila-Casado; Israel Perez-Torres; Ari Auron; Virgilia Soto; Teresa I Fortoul; Jaime Herrera-Acosta
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

9.  Methylated arginine derivatives in children and adolescents with chronic kidney disease.

Authors:  Ellen R Brooks; Craig B Langman; Sihe Wang; Heather E Price; Abigail L Hodges; Lara Darling; Amy Z Yang; Frederick A Smith
Journal:  Pediatr Nephrol       Date:  2008-10-02       Impact factor: 3.714

10.  Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.

Authors:  Alexander Koch; Sebastian Voigt; Carsten Kruschinski; Edouard Sanson; Hanna Dückers; Andreas Horn; Eray Yagmur; Henning Zimmermann; Christian Trautwein; Frank Tacke
Journal:  Crit Care       Date:  2011-02-16       Impact factor: 9.097

View more
  44 in total

1.  Is there clinical value in measuring suPAR levels in FSGS?

Authors:  Sanja Sever; Howard Trachtman; Changli Wei; Jochen Reiser
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-25       Impact factor: 8.237

Review 2.  Immunopathogenesis of idiopathic nephrotic syndrome with relapse.

Authors:  Djillali Sahali; Kelhia Sendeyo; Melanie Mangier; Vincent Audard; Shao Yu Zhang; Philippe Lang; Mario Ollero; Andre Pawlak
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

3.  The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?

Authors:  Björn Meijers; Ben Sprangers
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

4.  Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.

Authors:  Jutta Gellermann; Franz Schaefer; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2014-08-17       Impact factor: 3.714

5.  Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.

Authors:  Zhaoyang Peng; Jianhua Mao; Xuejun Chen; Fengqing Cai; Weizhong Gu; Haidong Fu; Huijun Shen; Jingjing Wang; Xia Jin; Xiujuan Zhu; Aimin Liu; Qiang Shu; Lizhong Du
Journal:  Pediatr Nephrol       Date:  2014-07-18       Impact factor: 3.714

6.  Reply: Measurement of serum suPAR is not ready for clinical use.

Authors:  Jeroen Deegens; Jack Wetzels
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

7.  Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor.

Authors:  Jeroen K Deegens; Jack F Wetzels
Journal:  Nat Rev Nephrol       Date:  2014-06-24       Impact factor: 28.314

8.  Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.

Authors:  Furong Li; Chunxia Zheng; Yongzhong Zhong; Caihong Zeng; Feng Xu; Ru Yin; Qi Jiang; Minlin Zhou; Zhihong Liu
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

Review 9.  Focal segmental glomerular sclerosis: do not overlook the role of immune response.

Authors:  Francesco Reggiani; Claudio Ponticelli
Journal:  J Nephrol       Date:  2016-02-20       Impact factor: 3.902

10.  Glomerular disease: A suPAR kidney connection found in the bone marrow.

Authors:  Lorenzo Gallon; Susan E Quaggin
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.